Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Tumor × alectinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 10 Neoplasm Metastasis 3 Neoplasms 2 Lung Neoplasms 2 Urinary Bladder Neoplasms 1 Solid Tumors 1 Rare Tumour 1 Rare Tumor 1 Hematologic Neoplasms 1 Genomic Instability 1 Gastrointestinal Neoplasms 1 Colorectal Neoplasms 1 Breast Neoplasms 1 Biliary Tract Neoplasms 1 Adenocarcinoma of Lung 1

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡